RET (V804L)
Sign in to save this workspaceRET · Variant type: point · HGVS: p.V804L
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Tenalisib | 100.0% | 0.0% | 97.98 |
| 2 | Selpercatinib | 99.8% | 0.2% | 96.72 |
| 3 | Pralsetinib | 99.8% | 0.2% | 93.43 |
| 4 | Tivozanib | 99.3% | 0.8% | 92.42 |
| 5 | Alpelisib | 98.5% | 1.6% | 97.22 |
| 6 | Fedratinib | 98.4% | 1.6% | 96.21 |
| 7 | Entrectinib | 97.9% | 2.1% | 93.69 |
| 8 | Ponatinib | 97.4% | 2.6% | 78.23 |
| 9 | Defactinib | 97.4% | 2.6% | 92.68 |
| 10 | Sunitinib | 97.3% | 2.7% | 91.73 |
| 11 | Gilteritinib | 96.4% | 3.6% | 88.97 |
| 12 | Nintedanib | 96.2% | 3.8% | 90.23 |
| 13 | Futibatinib | 93.7% | 6.3% | 98.48 |
| 14 | Brigatinib | 92.9% | 7.1% | 82.96 |
| 15 | Avapritinib | 92.2% | 7.8% | 97.73 |
| 16 | Repotrectinib | 82.6% | 17.4% | 84.21 |
| 17 | Alectinib | 82.1% | 17.9% | 95.49 |
| 18 | Regorafenib | 78.3% | 21.7% | 95.99 |
| 19 | Fostamatinib | 63.0% | 37.0% | 96.74 |
| 20 | Upadacitinib | 59.1% | 40.9% | 97.98 |
| 21 | Capivasertib | 58.9% | 41.1% | 96.48 |
| 22 | Sorafenib | 57.7% | 42.3% | 96.72 |
| 23 | Deucravacitinib | 57.0% | 43.0% | 98.99 |
| 24 | Baricitinib | 56.4% | 43.6% | 97.99 |
| 25 | Axitinib | 53.7% | 46.3% | 93.23 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Tenalisib | 100.0% | 98.5% | +1.5% |
| Selpercatinib | 99.8% | 100.0% | -0.2% |
| Pralsetinib | 99.8% | 100.0% | -0.2% |
| Tivozanib | 99.3% | 99.7% | -0.5% |
| Alpelisib | 98.5% | 99.6% | -1.2% |
| Fedratinib | 98.4% | 99.9% | -1.5% |
| Entrectinib | 97.9% | 99.6% | -1.7% |
| Ponatinib | 97.4% | 100.0% | -2.6% |
| Defactinib | 97.4% | — | — |
| Sunitinib | 97.3% | 97.2% | +0.1% |
| Gilteritinib | 96.4% | 100.0% | -3.6% |
| Nintedanib | 96.2% | 100.0% | -3.8% |
| Futibatinib | 93.7% | 97.7% | -4.0% |
| Brigatinib | 92.9% | 94.9% | -1.9% |
| Avapritinib | 92.2% | — | — |
| Repotrectinib | 82.6% | — | — |
| Alectinib | 82.1% | 97.8% | -15.7% |
| Regorafenib | 78.3% | 98.7% | -20.4% |
| Fostamatinib | 63.0% | — | — |
| Upadacitinib | 59.1% | — | — |
| Capivasertib | 58.9% | — | — |
| Sorafenib | 57.7% | 94.0% | -36.3% |
| Deucravacitinib | 57.0% | — | — |
| Baricitinib | 56.4% | — | — |
| Axitinib | 53.7% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_thyroid | Thyroid | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.5ms